Genome-wide Association Study

Withdrawn

• Conditions: Esophageal Squamous Cell Carcinoma

• Registration Number: NCT01498757
• Lead Sponsor: Samsung Medical Center

Brief Summary

To explore biomarkers predictive of clinical response to Taxane/5-FU/platinum based chemotherapy in esophageal squamous cell carcinoma. To identify negative predictive markers to 5-FU/platinum/Taxane. To elucidate signal transduction pathway attributable to 5-FU/platinum/Taxane resistance. To analyze correlation between the quantity of circulating tumor cells and circulating endothelial cell precursors and treatment response to Taxane/5-FU/platinum based chemotherapy.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2011-12-21
• Study First Submitted QC: 2011-12-21
• Study First Posted: 2011-12-23
• Study Start: 2012-01
• Primary Completion: 2012-06
• Study Completion: 2012-07-03
• Status Verified: 2019-05
• Last Update Submitted: 2019-05-17
• Last Update Posted: 2019-05-21

Recruitment & Eligibility

• Status: WITHDRAWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Histological confirmed esophageal squamous cell carcinoma
• Patients treated with Taxane or 5-FU or platinum based chemotherapy.
• provision of a signed written informed consent.

Exclusion Criteria

• patients not signed written informed consent.
• patient unacceptable for study in the judgement of the investigator.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Biomarkers predictive	24months	Biomarkers predictive of clinical response to Taxane or 5-fluorouracil or platinum based chemotherapy.

Trial Locations

Locations (1)

Samsung medical Center; 🇰🇷 Seoul, Korea, Republic of